IULIAN POPESCU, PhD, MD
The
Clinical Department of Radiobiology from the Fundeni Clinical Institute,
e-mail:
popdociul@yahoo.com
Alina Halpern, PhD, "Sf. Stefan" Hospital, Bucharest
Alina Halpern, PhD, "Sf. Stefan" Hospital, Bucharest
ABSTRACT
Since 2000 a new era has begun in the treatment of lung adeno-carcinoma
(ADC), which will improve, diversify, enrich the chemotherapy treatment of lung
cancer (PA) which becomes the targeted treatment for a heterogeneous disease. The
tyrosine-kinase inhibitors (ITK) have effect only upon ADC with EGFR mutations.
The most frequent mutations are at the level of the 19th exon through deletion and at the level of the 21st
exon through punctiform mutations
(T858R)
The EGFR and Kopi mutations, after the stimulation of ligands, undergo a
homo or heterodimerization, leading to the autophosphorylation of the ATP /
EGFR group, which in turn activate the pathways: PI3K/AKT, JAK/STAT and
Ras/MAPK which further lead to cellular growth, survival and proliferation. The
ITK blocks the ATP- EGFR phosphorylation, leading to the increase of cellular
apoptosis. But after a period